Pharmacokinetic Evaluation of Newly Developed Oral Immediate Release and Sustained Release Dosage Forms of Losartan Potassium
- *Corresponding Author:
- Basuvan Babu
JSS College of pharmacy
Off campus JSS University
E-mail: [email protected]
Received Date: October 16, 2012; Accepted Date: October 27, 2012; Published Date: October 29, 2012
Citation: Babu B, Meyyanathan SN, Gowramma B, Muralidharan S, Elango K, et al. (2012) Pharmacokinetic Evaluation of Newly Developed Oral Immediate Release and Sustained Release Dosage Forms of Losartan Potassium. J Bioequiv Availab 4: 121-127. doi: 10.4172/jbb.1000124
Copyright: © 2012 Babu B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The aim of our present study is to develop oral sustained release dosage form for Losartan Potassium (SS) with wet granulation technique. Xanthan gum with additives MCC PH101 was used for the present study. The dissolution study is carried out. The studies indicated that the drug release can be modulated by varying the concentration of the polymer and fillers. The pharmacokinetic parameters including AUC 0–t , AUC 0–∞ , C max , T max , T 1/2 , and elimination rate constant ( K el ) were determined from plasma concentration of both formulations of Immediate Release (Losartan Potassium 1.75 mg tablets) and Sustained Release (Losartan Potassium 3.5 mg tablets). The absorption of drug from the sustained release tablets was significantly higher than that for the reference Losartan Potassium tablet because of longer half-life and lower elimination. Different pharmacokinetic parameters including AUC 0-t , AUC 0-∞ , C max , T max , T 1/2 , and K eli were determined from plasma concentration of both Sustained and Immediate release tablets.